Indivior Pharmaceuticals, Inc. · Brief

Next report

117 days

Feb 25 · before openest.Q4 FY26

Expected move

±18.3%implied · straddle

28.9141.83

spot 35.37exp Mar 19ATM strike 35ATM straddle 7.60IV 42%

Oct 30 closeprovisionalthin chain

Expected move

4 reportsHistory

—≥ implied

Feb 26 '26±13.8%▲+0.24%×0.02

Q1 FY26±12.8%▲+7.70%×0.60

Q2 FY26—▼−6.60%—

Q3 FY26±12.3%▲+1.38%×0.11

quarterimplied−15%0+15%realized×

Q3 FY26±12.3%▲+1.38%×0.11

Q2 FY26—▼−6.60%—

Q1 FY26±12.8%▲+7.70%×0.60

Feb '26±13.8%▲+0.24%×0.02

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Feb 25 report · est.

Bull2 of 3

73.00%of Aquestive Therapeutics, Inc.'s revenue from INDVSEC filings

334managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

13 of 23of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

4tracked funds holding INDVN-PORT · Aug 31 '26

AI captions · Sep 16 '26once per report · top 2 per case

INDV report session

No linked exposure.

Oct 15impliedImplied move: ±11.9% into Oct 29 earnings (Oct 15 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.